Patent intelligence · US
US 9624228
Inhibitors of ERK and methods of use
Inhibitors of ERK and methods of use
Patent details — US 9624228
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 18, 2017
- Expiration
- Apr 13, 2037
- Applicant
- Kura Oncology, Inc.
- Claims
- 17
- CPC classes
- A61K, A61K31/4439, A61K31/4745, A61K31/513
Quick answer
US 9624228 (Inhibitors of ERK and methods of use) is held by Kura Oncology, Inc.. Status: granted. Granted Apr 18, 2017. Expires Apr 13, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Kura Oncology, Inc.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K31/4439, A61K31/4745, A61K31/513, A61K31/5377, A61K31/5517
More from Kura Oncology, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12410184
Crystalline forms of a menin inhibitor
granted -
US 12377026
Dental adhesive material kit
granted -
US 12358210
Resin composition for stereolithography
granted -
US 12344691
Resin composition for stereolithography
granted -
US 12214061
Adhesive composition for dental use
granted -
US 12208148
Dental restorative curable composition
granted -
US 12145888
Zirconia molded body and pre-sintered body capable of being sintered in short time
granted -
US 12138325
Dental composition
granted
Frequently asked questions
What is US patent 9624228?
US 9624228 (Inhibitors of ERK and methods of use) is held by Kura Oncology, Inc.. Status: granted. Granted Apr 18, 2017. Expires Apr 13, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9624228?
Kura Oncology, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 132 pharmaceutical patents for this assignee.
When does US 9624228 expire?
Our index shows an expiration date of Apr 13, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.